End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.69 USD | -0.89% | +11.07% | +166.25% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
Financials (USD)
Sales 2024 * | 2.01M | Sales 2025 * | 2.31M | Capitalization | 770M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -88M | EV / Sales 2024 * | 227 x |
Net cash position 2024 * | 314M | Net cash position 2025 * | 518M | EV / Sales 2025 * | 109 x |
P/E ratio 2024 * |
-12
x | P/E ratio 2025 * |
-10.1
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.16% |
1 day | -0.89% | ||
1 week | +11.07% | ||
Current month | +29.70% | ||
1 month | +14.71% | ||
3 months | +14.90% | ||
6 months | +141.83% | ||
Current year | +166.25% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 26.25 | -5.20% | 90,942 |
24-05-15 | 27.69 | -0.89% | 114,608 |
24-05-14 | 27.94 | +7.42% | 96,629 |
24-05-13 | 26.01 | +7.08% | 103,074 |
24-05-10 | 24.29 | -2.57% | 98,030 |
End-of-day quote Nasdaq, May 14, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+166.25% | 770M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.41% | 22.28B | |
-11.90% | 22.41B | |
-5.99% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- DNTH Stock